JGIA
AVDL

Jackson Grant Investment Advisers’s Avadel Pharmaceuticals AVDL Stock Holding History

Jackson Grant Investment Advisers’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-250
Closed -$1K – 243
2018
Q3 		$1K Buy
+250
New +$1.35K ﹤0.01% 209
2018
Q2 		– Sell
-250
Closed -$2K – 216
2018
Q1 		$2K Hold
250
– – ﹤0.01% 207
2017
Q4 		$2K Sell
250
-250
-50% -$2.34K ﹤0.01% 208
2017
Q3 		$5K Buy
+500
New +$4.77K ﹤0.01% 203

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Jackson Grant Investment Advisers's AVDL Position: Q4 2018 in Review

Jackson Grant Investment Advisers sold out of Avadel Pharmaceuticals (AVDL) in Q4 2018, closing a stake of 250 shares — an estimated $1K sold.

Jackson Grant Investment Advisers first reported a position in AVDL in Q3 2017 and held it in 4 quarters. The position peaked at $5K in Q3 2017. 59 funds tracked by Wall St. Rank hold AVDL as of Q4 2018.

  • Jackson Grant Investment Advisers reported no remaining Avadel Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Jackson Grant Investment Advisers sold 250 Avadel Pharmaceuticals shares in Q4 2018, an estimated $1K.
  • Jackson Grant Investment Advisers first reported a position in Avadel Pharmaceuticals in Q3 2017 and held it in 4 quarters.
  • Jackson Grant Investment Advisers's Avadel Pharmaceuticals position peaked at $5K in Q3 2017.
  • 59 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2018.

Based on Jackson Grant Investment Advisers's 13F filing for Q4 2018, filed 23 Jan 2019.